- Home
- CRVS vs NDMO Comparison
CRVS vs NDMO Comparison
Compare CRVS & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NDMO
- Stock Information
- Founded
- CRVS 2014
- NDMO 2019
- Country
- CRVS United States
- NDMO United States
- Employees
- CRVS N/A
- NDMO N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- CRVS Health Care
- NDMO Finance
- Exchange
- CRVS Nasdaq
- NDMO Nasdaq
- Market Cap
- CRVS 516.0M
- NDMO 596.2M
- IPO Year
- CRVS 2016
- NDMO N/A
- Fundamental
- Price
- CRVS $4.99
- NDMO $9.94
- Analyst Decision
- CRVS Buy
- NDMO
- Analyst Count
- CRVS 4
- NDMO 0
- Target Price
- CRVS $12.83
- NDMO N/A
- AVG Volume (30 Days)
- CRVS 1.6M
- NDMO 218.6K
- Earning Date
- CRVS 11-12-2024
- NDMO 01-01-0001
- Dividend Yield
- CRVS N/A
- NDMO 6.75%
- EPS Growth
- CRVS N/A
- NDMO N/A
- EPS
- CRVS N/A
- NDMO N/A
- Revenue
- CRVS N/A
- NDMO N/A
- Revenue This Year
- CRVS N/A
- NDMO N/A
- Revenue Next Year
- CRVS N/A
- NDMO N/A
- P/E Ratio
- CRVS N/A
- NDMO N/A
- Revenue Growth
- CRVS N/A
- NDMO N/A
- 52 Week Low
- CRVS $1.30
- NDMO $8.99
- 52 Week High
- CRVS $10.00
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- CRVS 28.00
- NDMO 19.56
- Support Level
- CRVS $3.77
- NDMO $10.50
- Resistance Level
- CRVS $7.44
- NDMO $10.43
- Average True Range (ATR)
- CRVS 0.60
- NDMO 0.17
- MACD
- CRVS -0.41
- NDMO -0.08
- Stochastic Oscillator
- CRVS 25.85
- NDMO 1.40
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.